title: The value of oxybutynin in transdermal patches for treating overactive bladder.
abstract: BACKGROUND
  There is currently a broad therapeutic arsenal of drugs for treating overactive bladder syndrome (OAB). However, there is still a need for new compounds and for improving known drugs in terms of efficacy, compliance and tolerability.
  
  
  OBJECTIVE
  To report the scientific evidence on the safety and efficacy of transdermal oxybutynin (OXY-TDS) for treating OAB.
  
  
  METHODS
  A systematic review without time restrictions was conducted until May 2015 in the MEDLINE/PubMed database. We also performed a manual review of abstracts published in international urogynaecology congresses.
  
  
  RESULTS
  The evaluated studies show that patients treated with OXY-TDS experience a significant reduction in urinary incontinence episodes compared with placebo, which is comparable to that observed in patients treated with oral oxybutynin or with tolterodine. In all of the studies, we observed improvements in symptoms from the second or third week of treatment and in a sustained manner until the end of treatment (6, 12 or 24 weeks). The clinical practice study also showed improved quality of life, achieving benefits in numerous patient profiles, with an efficacy independent of previous treatments. The safety of the drug was demonstrated in the various patient profiles.
  
  
  CONCLUSIONS
  OXY-TDS represents an effective alternative for the symptomatic treatment of adult patients with OAB, which, thanks to its pharmacokinetic profile, better tolerability, different administration method and dosage, could represent an added value in treating special populations.
authors: Servicio de Urología, Hospital Clínico San Carlos, Madrid, España. Electronic address: jsalinascasado@yahoo.es.
authors: J
authors: J
authors: Salinas-Casado
authors: Servicio de Urología, Hospital Nacional de Parapléjicos, Toledo, España.
authors: M
authors: M
authors: Esteban-Fuertes
authors: Gebro Pharma, Barcelona, España.
authors: O
authors: O
authors: Serrano
authors: Gebro Pharma, Barcelona, España.
authors: J
authors: J
authors: Galván
mesh_terms: D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage*; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D057968:Transdermal Patch; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin
keywords: Administración transdérmica; Anticholinergic agents; Anticolinérgicos; Incontinencia urinaria; Overactive bladder; Oxibutinina; Oxibutinina transdérmica; Oxybutynin; Transdermal administration; Transdermal oxybutynin; Urinary incontinence; Vejiga hiperactiva